HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Another breakthrough has been with ADCs in combination with other treatments, such as an immunotherapy that inhibits the ...

Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.

First Drug Is Expected To Be Available In Market By 2029 Says Kuick In Its ReportDelhi, Sept. 17, 2024 (GLOBE NEWSWIRE) -- ...

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat ...

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain ...

Recent Studyt By Kuick highlights more than 600 Cancer Antibody Drug conjugates in Clinical TrialsDelhi, Sept. 19, 2024 ...

Phase I data presented at ESMO suggested that TORL-1-23 may have particularly strong activity in CLDN-positive advanced ...